A study to determine the performance characteristics of a novel urine based bladder cancer test (uRNA-2) which detects RNA markers in urine, on patients undergoing monitoring for recurrence of bladder cancer

Pacific Edge PTY Ltd.0 个研究点目标入组 300 人开始时间: 2012年1月10日最近更新: 2020年1月13日

适应症

试验速览

暂无简介。

•1.Positive primary or recurrence diagnosis for urinary tract TCC within the past 5 years and confirmation by histopathological examination of resected tissue
•confirmation by histopathological examination of biopsy tissue
•2.Patient is undergoing investigative cystoscopies for the monitoring of recurrence of urinary tract TCC at intervals prescribed by clinical practitioner
•3.Patient is able to provide a voided urine sample of the required minimum volume
•4.Patient is able to give written informed consent
•5.Patient is able and willing to comply with study requirements

•1.Prior genitourinary manipulation in the 14 days before urine collection,
•2.Current symptoms specific to urinary tract infection as evident on preliminary examination
•3.Current or known history of urinary tract inflammatory disorder,
•4.Recent history of glomerulonephritis, nephrosis or other renal inflammatory disorders,
•5.Recent history of pyelonephritis
•6.Total cystectomy of the bladder

发起方

Pacific Edge PTY Ltd.